News from bioinvent A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

01 Jul, 2020, 09:28 BST BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has further extended the research term under its...


30 Jun, 2020, 12:40 BST BioInvent Submits a CTA for a Phase I/IIa trial of BI-1808, A First-in-class Anti-TNFR2 Antibody for the Treatment of Patients With Solid Tumors and CTCL

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


23 Jun, 2020, 10:07 BST BioInvent Enrolls First Patient in Phase I/IIa Trial of BI-1206 in Combination With KEYTRUDA® for the Treatment of Patients With Solid Tumors

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


22 Jun, 2020, 14:51 BST BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


22 Jun, 2020, 14:36 BST BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


18 Jun, 2020, 14:21 BST Proposal for a New Board Member to be Elected at the Extraordinary General Meeting on July 3, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces, on behalf of the nomination committee and major shareholders, the proposal to...


15 May, 2020, 07:49 BST BioInvent and Transgene Present Preclinical Data Demonstrating BT-001's Powerful Activity Against Solid Tumors

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


15 May, 2020, 07:41 BST BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces the presentation of promising new data on its anti-tumor necrosis factor...


30 Apr, 2020, 07:21 BST BioInvent Signs New Manufacturing Agreement With U.S. Cell Therapy Company

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


28 Apr, 2020, 07:17 BST BioInvent Interim Report January 1 - March 31, 2020

Promising progress reported for BI-1206 in combination with rituximab "We have made a strong start to 2020 and remain on track to deliver on our...


14 Apr, 2020, 07:27 BST BioInvent Reports Promising Progress in Phase I/lla Trial of Lead Program BI-1206 in Combination with Rituximab

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today provides a preliminary insight into progress of its Phase I/IIa trial of ...


08 Apr, 2020, 11:40 BST BioInvent: Annual Report 2019

BioInvent International AB (publ) (BINV) today announced that the Annual Report for 2019 is available at the company's website, www.bioinvent.com...


26 Mar, 2020, 14:03 GMT BioInvent Postpones the Annual General Meeting and Provides an Update on the Current Situation in Respect of COVID-19

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces that the Board of Directors has resolved to postpone the annual general meeting ...


24 Mar, 2020, 13:24 GMT BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206

BioInvent International AB ("BioInvent") (OMXS: BINV) today announces an agreement with SkylineDx to characterize the gene expression and...


03 Mar, 2020, 08:04 GMT BioInvent and Transgene to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


27 Feb, 2020, 06:54 GMT BioInvent Financial Statement January 1 - December 31, 2019

"We are proud that we have delivered on our goals for the year and feel confident that we will continue to do so in 2020, with a number of important...


24 Feb, 2020, 14:14 GMT Invitation to Presentation of BioInvent's Fourth Quarter Report 2019 on February 27, 2020

BioInvent International AB (OMXS: BINV) will issue its interim report for the fourth quarter 2019 on Thursday February 27 at 7.30 a.m. CET, followed...


23 Dec, 2019, 09:26 GMT BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc.

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the...


18 Dec, 2019, 07:16 GMT BioInvent Has Entered Into a Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1206 in Combination With KEYTRUDA® in Advanced Solid Tumors

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that it has entered into a clinical trial collaboration and...


11 Dec, 2019, 08:02 GMT BioInvent and Transgene Announce Compelling Preclinical Data for BT-001 in Solid Tumors

BioInvent International AB (publ) (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class...


08 Nov, 2019, 07:35 GMT BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019

BioInvent International AB (publ) (OMXS: BINV) today announces it will make a poster presentation with preclinical data on BI-1206 at the annual...


23 Oct, 2019, 12:48 BST BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)

BioInvent International AB (publ) (OMXS: BINV) today announces it has concluded a production agreement with Cancer Research UK, the world's largest...


22 Aug, 2019, 07:47 BST BioInvent: Interim Report January 1 - June 30, 2019

"We are executing according to plan. Our lead candidate BI-1206 has shown encouraging initial data in hematological cancers, and has now also entered ...


21 Aug, 2019, 08:19 BST BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory...


20 Aug, 2019, 09:54 BST BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME

BioInvent International AB's (publ) (OMXS: BINV) partner Oxurion NV has today reported topline data from a Phase lla study evaluating THR-317, a...